-
1 Comment
Balaxi Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 6.5% below its 200 day moving average.
From a valuation standpoint, the stock is 5.1% cheaper than other stocks from the Other sector with a price to sales ratio of 2.2.
Balaxi Pharmaceuticals Limited's total revenue rose by 402.1% to $660M since the same quarter in the previous year.
Its net income has increased by 343.0% to $110M since the same quarter in the previous year.
Finally, its free cash flow grew by 120.3% to $17M since the same quarter in the previous year.
Based on the above factors, Balaxi Pharmaceuticals Limited gets an overall score of 4/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| Sector | Healthcare |
| ISIN | INE618N01022 |
| Industry | Biotechnology |
| Market Cap | 3B |
|---|---|
| PE Ratio | 11.44 |
| Target Price | None |
| Beta | 0.59 |
| Dividend Yield | None |
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. Balaxi Pharmaceuticals Limited was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BALAXI.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
